A Phase I trial involving ten patients with relapsed or refractory classical Hodgkin lymphoma or T-cell lymphoma has achieved ...

In the healthy state, T cells are genetically programmed to survey ... Consequently, differentiating mycosis fungoides from benign rashes can be challenging. In fact, it is not uncommon for ...

More information: Sandeep S. Raj et al, An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma, Nature Medicine (2025). DOI: 10.1038/s41591-025-03532-x ...

or CAR T cell therapy, where a patient's immune cells are taken out, grown and modified to specifically target certain cancers such as the aggressive lymphoma Cannella had. When he was first ...

and MSK have created a tool that uses machine learning to assess a non-Hodgkin lymphoma (NHL) patient's likely response to chimeric antigen receptor (CAR) T cell therapy before starting the ...

This trial enrolled 37 adult patients with CD30-positive Hodgkin lymphoma and five with T-cell lymphoma. Patients were heavily pretreated and were refractory to brentuximab vedotin and anti-PD1 ...

Researchers from the Sant Pau Research Institute (IR Sant Pau), in collaboration with Sant Pau Hospital and the Josep ...